Gilead Sciences Inc

Research Gilead Sciences Inc (GILD) on Bullrun: valuation model: 11.2% undervalued, market cap USD 156.85B, P/E 17.2, dividend yield 2.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGILD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal11.2% undervalued
• Market capUSD 156.85B
• P/E17.2
• Dividend yield2.5%
• Financial periodFY2025
• RevenueUSD 29.44B
• Revenue growth2.4%
• Net incomeUSD 8.51B
• Free cash flowUSD 9.46B
• Gross margin78.8%

Valuation Snapshot

Bullrun's latest valuation model marks Gilead Sciences Inc as 11.2% undervalued; latest market cap is USD 156.85B; P/E is 17.2; dividend yield is 2.5%.

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus;

Frequently asked questions

Is Gilead Sciences Inc overvalued or undervalued?

Bullrun's valuation model currently marks Gilead Sciences Inc as 11.2% undervalued.

What is Gilead Sciences Inc's market cap?

Gilead Sciences Inc's market capitalization is USD 156.85B.

What is Gilead Sciences Inc's P/E ratio?

Gilead Sciences Inc's price-to-earnings (P/E) ratio is 17.2.

Does Gilead Sciences Inc pay a dividend?

Gilead Sciences Inc has a dividend yield of 2.5%.

What does Gilead Sciences Inc do?

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.